US Patent 9,956,183: Scope, Claims, Exclusivity and Patent Landscape for Cannabidiol With Clobazam
US Patent 9,956,183 protects a specific cannabidiol-clobazam treatment strategy for treatment-resistant Lennox-Gastaut syndrome and Dravet syndrome. The central limitation is not cannabidiol alone. The claims require a qualifying childhood-onset epilepsy, prior treatment with clobazam or cannabidiol plus clobazam, continued co-administration of cannabidiol and clobazam, and a reduction in the clobazam dose. The claims also impose a cannabidiol purity threshold of at least 98% and a THC limit of 0.15% or less.
The patent is associated with the Epidiolex development program and is directed principally to a drug-drug interaction and dose-management approach. It does not broadly cover every use of cannabidiol in epilepsy.
What does US Patent 9,956,183 protect?
Patent 9,956,183 protects methods of treating or reducing seizures in patients with:
- Lennox-Gastaut syndrome, or LGS;
- Dravet syndrome;
- Treatment-resistant, childhood-onset epilepsy;
- Prior exposure to clobazam, or to cannabidiol and clobazam;
- Continued treatment with cannabidiol and clobazam;
- A reduced clobazam dose after cannabidiol is introduced or used in combination;
- Cannabidiol with at least 98% w/w purity;
- THC content of no more than 0.15% w/w.
Claims 1 through 4 and 17 cover the first treatment pathway: the patient was previously treated with clobazam, cannabidiol is introduced, and the clobazam dose is reduced relative to the earlier dose.
Claims 5 through 16 and 18 cover the second pathway: the patient was previously treated with cannabidiol and clobazam, and the clobazam dose is reduced relative to the prior dose.
The patent therefore covers dose adjustment in an existing combination regimen rather than a fixed cannabidiol formulation alone.
How are the claims organized?
| Claim group |
Required disease |
Prior treatment |
Required intervention |
Additional limitation |
| 1 |
LGS or Dravet syndrome |
Clobazam |
CBD plus reduced clobazam |
CBD at least 98% pure; THC no more than 0.15% |
| 2 |
LGS |
Same as claim 1 |
Same |
Narrowed disease |
| 3 |
Dravet syndrome |
Same as claim 1 |
Same |
Narrowed disease |
| 4 |
LGS or Dravet syndrome |
Same as claim 1 |
Same |
Reduced total convulsive seizure frequency |
| 5 |
LGS or Dravet syndrome |
CBD plus clobazam |
CBD plus reduced clobazam |
CBD at least 98% pure; THC no more than 0.15% |
| 6 |
LGS or Dravet syndrome |
CBD plus clobazam |
Same |
CBD contains THC, subject to the claim 5 ceiling |
| 7 |
LGS or Dravet syndrome |
Same as claim 5 |
Same |
Reduced total convulsive seizure frequency |
| 8 |
LGS |
CBD plus clobazam |
Same |
Narrowed disease |
| 9-11 |
LGS |
CBD plus clobazam |
Same |
CBD dose at least 5, 10 or 15 mg/kg/day |
| 12 |
Dravet syndrome |
CBD plus clobazam |
Same |
Narrowed disease |
| 13-15 |
Dravet syndrome |
CBD plus clobazam |
Same |
CBD dose at least 5, 10 or 15 mg/kg/day |
| 16 |
Dravet syndrome |
CBD plus clobazam |
Same |
Reduced total convulsive seizure frequency |
| 17 |
LGS or Dravet syndrome |
Clobazam |
Treatment of seizures with CBD plus reduced clobazam |
CBD purity and THC limits |
| 18 |
LGS or Dravet syndrome |
CBD plus clobazam |
Treatment of seizures with reduced clobazam |
CBD purity and THC limits |
Claims 2, 3, 8 and 12 narrow the disease. Claims 9 through 15 add dose thresholds. Claims 4, 7 and 16 add a specific therapeutic result. Claims 17 and 18 use "treating seizures" rather than "reducing seizure frequency," but otherwise track the principal methods in claims 1 and 5.
What are the most important claim limitations?
The epilepsy must be LGS or Dravet syndrome
The disease limitation is material. A product or regimen used for focal epilepsy, juvenile myoclonic epilepsy, tuberous sclerosis complex, or another seizure disorder would not fall within the literal scope unless the patient also had the claimed LGS or Dravet diagnosis.
The claims also require treatment-resistant, childhood-onset epilepsy. The patent does not define every possible evidentiary requirement for those terms in the claim language. In a dispute, medical records, diagnosis codes, treatment history, seizure burden and prior medication failures would likely be relevant.
The patient must have prior clobazam exposure
The first claim set requires that the patient was previously treated with clobazam. The second claim set requires previous treatment with CBD and clobazam.
This limitation makes the claims narrower than a claim covering initial combination therapy. A patient receiving cannabidiol and clobazam for the first time may not satisfy the prior-treatment limitation.
The clobazam dose must be reduced
The dose-reduction requirement is the patent's principal commercial limitation. The claims require that the clobazam dose used with cannabidiol is reduced relative to:
- The dose administered before cannabidiol treatment, or
- The previous dose in a prior CBD-clobazam regimen.
No specific percentage reduction appears in the supplied claims. A modest reduction may be sufficient if it is documented and satisfies the claim construction adopted by a court. The claim does not expressly require that the reduction be caused by a measured pharmacokinetic increase in N-desmethylclobazam, although that interaction provides the clinical rationale.
The FDA Epidiolex label recognizes that cannabidiol can increase exposure to clobazam's active metabolite, N-desmethylclobazam, and states that clobazam dose reduction should be considered when adverse reactions associated with clobazam occur.[1]
Cannabidiol must be highly purified
The claims require CBD purity of at least 98% w/w. This limitation distinguishes the claims from broad claims directed to cannabis extracts or pharmaceutical compositions containing undefined CBD concentrations.
The THC ceiling is no more than 0.15% w/w. Claim 6 confirms that the claimed CBD may contain THC, provided it remains within the specified limit. The patent therefore does not require absolute THC absence.
What is the likely patent term and exclusivity timeline?
| Event |
Date or status |
| US Patent 9,956,183 issued |
May 1, 2018 |
| Patent term basis |
20 years from the relevant nonprovisional filing or priority framework |
| Reported expiration date |
June 26, 2035 |
| Pediatric exclusivity |
May extend applicable FDA exclusivity by six months if granted and tied to qualifying studies |
| Regulatory product most closely associated with the patent |
Epidiolex oral solution |
| Active ingredient |
Cannabidiol |
| Primary FDA indications |
Seizures associated with LGS, Dravet syndrome and tuberous sclerosis complex in specified age groups |
The June 26, 2035 date is the operative reported expiration date for the patent family position associated with this protection. The effective market-exclusivity date must be assessed with the full Orange Book record, any patent-term adjustment, terminal disclaimer, pediatric exclusivity and later-listed continuation patents.[2]
Patent expiry does not eliminate other barriers. A competitor may face separate formulation, manufacturing, method-of-use or regulatory patents covering cannabidiol products.
What is the Orange Book status of US 9,956,183?
US 9,956,183 has been associated with the Epidiolex patent estate and the FDA-listed indication involving seizures associated with LGS and Dravet syndrome. An Orange Book-listed method-of-use patent can support a Paragraph IV certification dispute when an ANDA applicant seeks approval for a product that would be used for the protected indication.[2]
The key regulatory issue is whether the proposed generic label would include the patented method. A generic applicant can attempt a section viii statement that omits a patented indication or dosing instruction. That strategy is more difficult when the proposed label expressly includes:
- LGS or Dravet syndrome;
- Concomitant clobazam use;
- Dose reduction of clobazam after CBD administration; or
- Language that encourages the claimed treatment method.
The practical infringement question is label-driven. A generic cannabidiol product with the same active ingredient and purity may not infringe merely because it is chemically equivalent. Risk increases if the labeling, promotional materials or standard dosing instructions direct physicians to reduce clobazam in the claimed patient population.
How strong is the patent estate for Epidiolex?
The estate is strongest against a product that reproduces the full clinical regimen. It is weaker against products that avoid one or more required elements.
| Potential design-around |
Exposure under Patent 9,956,183 |
| CBD monotherapy |
Lower, because clobazam co-administration is required |
| CBD plus clobazam without reducing clobazam |
Lower on literal claim scope |
| CBD plus clobazam in focal epilepsy |
Lower, because LGS or Dravet syndrome is required |
| Low-purity cannabis extract |
Lower, because CBD purity must reach 98% |
| CBD with THC above 0.15% |
Outside the supplied claim limitations |
| CBD plus clobazam in a patient without prior clobazam use |
Potentially outside claims 1 and 17 |
| CBD plus clobazam in a patient with no prior combination treatment |
Potentially outside claims 5-16 and 18 |
| CBD product labeled for LGS or Dravet syndrome with clobazam dose reduction |
High exposure |
The patent has meaningful combination-regimen value but limited composition-of-matter breadth. It does not prevent all cannabidiol products, all epilepsy indications or all use of CBD with antiseizure drugs.
What formulation patents protect cannabidiol products?
Patent 9,956,183 is primarily a method-of-treatment patent. It does not, based on the supplied claims, require a particular oral solution, excipient system, bottle, concentration or manufacturing process.
Separate patent families may address:
- Pharmaceutical-grade CBD purification;
- Oral cannabidiol solutions;
- Solubility and dispersion systems;
- Flavoring and preservative systems;
- Dose uniformity;
- Stability and storage;
- Manufacturing processes for high-purity CBD;
- Methods of reducing THC and other cannabinoids.
These additional families can create independent barriers even if a competitor avoids the method claims in Patent 9,956,183. A complete freedom-to-operate review must distinguish the active ingredient, finished formulation, manufacturing route and proposed FDA label.
What manufacturing and intellectual-property barriers affect generic entry?
The 98% purity requirement creates a product-quality boundary. A competitor would need to demonstrate consistent CBD purity and THC control through raw-material sourcing, extraction, purification, analytical testing and batch release.
Manufacturing risk can arise from:
- Residual THC variation;
- Conversion or degradation products;
- Batch-to-batch cannabinoid profiles;
- Analytical-method differences;
- Stability failures;
- Solvent residues;
- Impurities generated during purification.
These issues may support regulatory objections or separate process-patent claims. They do not automatically establish infringement of Patent 9,956,183, which focuses on the treatment method and product purity.
Which companies challenge the Epidiolex patent estate?
The commercially relevant challengers are generic pharmaceutical companies capable of filing an ANDA for cannabidiol oral solution. Publicly documented Paragraph IV activity must be evaluated patent by patent because a company may challenge one Orange Book listing while accepting others.
The principal potential entrant categories are:
- Generic manufacturers filing ANDAs for cannabidiol oral solution.
- Specialty pharmaceutical companies developing synthetic or highly purified CBD.
- Cannabis-derived CBD manufacturers seeking pharmaceutical approval.
- Developers of alternative antiseizure products that compete clinically without practicing the claimed CBD-clobazam regimen.
The supplied record does not establish a specific Paragraph IV notice, ANDA filer or active litigation proceeding directed to Patent 9,956,183. A definitive litigation conclusion cannot be drawn from the claims alone.
What litigation and settlement issues matter?
A Paragraph IV case involving this patent would likely focus on:
- Whether the proposed label induces the claimed dose reduction;
- Whether the patient population is limited to LGS and Dravet syndrome;
- Whether "previously treated" requires a particular duration or dose;
- Whether the generic CBD meets the 98% purity limitation;
- Whether THC is present and, if so, whether it remains at or below 0.15%;
- Whether a physician's dose adjustment is attributable to the generic label;
- Whether section viii labeling can omit the protected method.
A settlement could include a delayed generic launch, a license for a narrow indication, a covenant not to sue, or a label carve-out. No settlement terms should be inferred without a filed agreement, court order or regulatory record.
How does Patent 9,956,183 compare with competing epilepsy therapies?
| Therapy |
Company or originator |
Role in LGS or Dravet syndrome |
Relevance to Patent 9,956,183 |
| Epidiolex |
Jazz Pharmaceuticals, following GW Pharmaceuticals acquisition |
Purified cannabidiol |
Directly associated with the claimed CBD-clobazam strategy |
| Clobazam |
Multiple manufacturers; branded Onfi historically associated with Lundbeck |
Common adjunctive antiseizure therapy |
Required combination drug |
| Fintepla |
Jazz Pharmaceuticals, originally Zogenix |
Approved for Dravet syndrome and LGS |
Competes therapeutically but does not practice the CBD limitation |
| Diacomit |
Biocodex |
Dravet syndrome adjunctive therapy |
Alternative to or component of multi-drug regimens |
| Rufinamide |
Generic and branded products |
LGS therapy |
Competing treatment, outside CBD claims |
| Valproate and topiramate |
Multiple manufacturers |
Broad antiseizure use |
Background therapies, not covered by the patent |
The patent does not block competing non-CBD therapies. Its commercial value depends on the extent to which clinicians use CBD with clobazam in the two named syndromes and reduce clobazam dosing.
What generic launch risks exist?
A generic launch could proceed through several scenarios:
Full-label challenge
A generic applicant keeps LGS and Dravet syndrome indications and includes language addressing concomitant clobazam. This presents the highest method-patent risk and may trigger a Paragraph IV dispute.
Carved-out label
The applicant removes or narrows the patented use. The commercial value depends on whether physicians can still prescribe the generic for the protected use based on ordinary medical practice. Litigation risk may remain if the label encourages the patented regimen indirectly.
Post-expiry launch
The applicant accepts the patent and launches after the reported June 26, 2035 expiration date, subject to other Orange Book patents and exclusivities.
Non-infringing clinical positioning
A competing CBD product could target a different seizure disorder, use CBD without clobazam, or avoid instructions requiring clobazam reduction. That approach reduces exposure to this patent but may not avoid other patent families.
What is the geographic coverage?
US Patent 9,956,183 is enforceable in the United States only. Foreign counterparts may protect related subject matter in Europe, the United Kingdom, Canada, Australia and other jurisdictions, but claim scope, prosecution history and expiry dates differ by country.
The international risk analysis must examine:
- National-phase or direct foreign filings;
- Granted claims and pending continuations;
- Supplementary protection certificates;
- Local patent-term adjustments;
- Regulatory data exclusivity;
- National rules on induced infringement and skinny labeling.
US claim scope cannot be exported directly to another jurisdiction.
Key Takeaways
- Patent 9,956,183 is a narrow but commercially relevant method patent for CBD plus reduced-dose clobazam.
- The required diseases are treatment-resistant childhood-onset LGS and Dravet syndrome.
- Prior clobazam exposure, or prior CBD-clobazam treatment, is required depending on the claim set.
- CBD must be at least 98% pure and contain no more than 0.15% THC.
- The claims do not cover CBD monotherapy or every CBD epilepsy use.
- Claims 9-15 add CBD dose thresholds of 5, 10 and 15 mg/kg/day.
- The reported patent expiration date is June 26, 2035.
- Orange Book and later Epidiolex-related patents must be reviewed before assessing a generic launch date.
- The highest infringement risk arises from an ANDA label directing use of CBD with clobazam and recommending clobazam dose reduction for LGS or Dravet syndrome.
- A complete freedom-to-operate analysis must separately review formulation, manufacturing, purification and other method-of-use patents.
FAQs
Does Patent 9,956,183 cover all Epidiolex prescriptions?
No. It covers only regimens meeting the claimed disease, prior-treatment, combination, dose-reduction, purity and THC limitations.
Can a generic cannabidiol product avoid this patent by omitting clobazam from its label?
Potentially, but the product may face other patents or induced-infringement arguments if its labeling or marketing encourages the claimed combination.
Is a CBD product with zero THC outside the patent?
No. Zero THC satisfies the limitation requiring no more than 0.15% THC, assuming all other claim elements are met.
Does the patent require a 50% reduction in clobazam?
No specific reduction percentage appears in the supplied claims. The claims require a reduction relative to the prior clobazam dose.
Does the patent block fenfluramine or stiripentol for Dravet syndrome?
No. Those products do not contain the claimed CBD-plus-clobazam regimen and are not blocked by this patent on the supplied claim language.
References
-
U.S. Food and Drug Administration. (2023). Epidiolex (cannabidiol) oral solution: Prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
-
United States Patent and Trademark Office. (2018). U.S. Patent No. 9,956,183, cannabidiol in the treatment of epilepsy. USPTO.
-
U.S. Food and Drug Administration. (2018). FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. FDA.
